Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Target ID: TTDS00200

Target Information
NameCGMP-inhibited 3',5'-cyclic phosphodiesterase    
Type of targetSuccessful target    
SynonymsCAMP phosphodiesterase III    
CGI-PDE    
Cyclic AMP phosphodiesterase III    
Cyclic GMP inhibited phosphodiesterase    
PDE3    
Phosphodiesterase 3    
Phosphodiesterase III    
DiseaseAsthma
[ICD9: 493   ICD10: J45]
[1]
Atopic dermatitis
[ICD9: 691.8   ICD10: L20]
[2]
Hepatic ischemia-reperfusion injury
[ICD9: 459.89   ICD10: I99.8]
[3]
Malignant tumors
[ICD9: 140-199, 210-229   ICD10: C00-C75, C7A, C7B, D10-D36, D3A]
[4]
Peripheral arterial disease
[ICD9: 443.9   ICD10: I73.9]
[5]
Tumors
[ICD9: 140-199, 210-229   ICD10: C00-C75, C7A, C7B, D10-D36, D3A]
[4]
Vascular disease
[ICD9: 325, 430-459   ICD10: G45-G46, I60-I95]
[6]
Drug(s)AmrinoneApprovedCongestive heart failure[3]
EnoximoneApprovedCongestive heart failure[7]
OxtriphyllineApprovedCough[1]
EC NumberEC 3.1.4.17
Related US Patent6,255,303
6,403,597
6,498,173
6,541,487
6,610,746
Target ValidationClick to Find Target Validation Information.    
InhibitorAmrinone[3]
Cilostamide[4]
Enoximone[7]
Olprinone[6]
Oxtriphylline[1]
R 80122[8]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. To Reference
Ref 2Phosphodiesterase and immune dysfunction in atopic dermatitis. J Dermatol Sci. 1990 Jan;1(1):1-6. To Reference
Ref 3Effects of amrinone on hepatic ischemia-reperfusion injury in rats. J Hepatol. 2002 Jul;37(1):31-8. To Reference
Ref 4Phosphodiesterase 3 as a potential target for therapy of malignant tumors in the submandibular gland. Anticancer Drugs. 2001 Jan;12(1):79-83. To Reference
Ref 5Treating peripheral arterial disease in patients with diabetes. Diabetes Obes Metab. 2002 Mar;4 Suppl 2:S26-31. To Reference
Ref 6Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev. 2002 Fall;20(3):163-74. To Reference
Ref 7Combined use of ultra-short acting beta-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximone. Expert Opin Pharmacother. 2007 Sep;8(13):2135-47. To Reference
Ref 8Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds. J Pharmacol Exp Ther. 1992 Oct;263(1):6-14. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543